Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Pub...
09 July 2020 - 10:30PM
Medexus Pharmaceuticals Inc. (the “Company” or
“Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to
announce that Triamcinolone Hexacetonide Injectable Suspension 20
mg/mL (TH) has been approved for inclusion on the Alberta Drug
Benefit List (ADBL), the Saskatchewan Drug Plan, the Newfoundland
and Labrador Prescription Drug Program (NLPDP) and the Yukon Drug
Formulary for the treatment of Juvenile Idiopathic Arthritis (JIA).
TH has also been approved for inclusion on the Ontario Drug Benefit
Formulary/Comparative Drug Index (ODB Formulary/CDI) and the
Non-Insured Health Benefits – Drug Benefit List for its full Health
Canada-approved indication which includes approved use in both
adults and adolescents. TH is the longest acting corticosteroid for
intra-articular injection, often lasting twice as long as
comparator products.
Ken d’Entremont, Chief Executive Officer of
Medexus, commented, “The inclusion of our TH on these public drug
plan formularies in Canada enhances the accessibility of this
therapy for pediatric and adult patients suffering from chronic
inflammatory diseases including JIA and RA. Previously, both
younger and adult patients with subacute and chronic inflammatory
joint diseases have had difficulty getting TH due to a
long-standing shortage of Triamcinolone Hexacetonide in Canada. We
look forward to advancing the commercial rollout of our TH in
additional provinces across Canada. Moreover, we believe our
formulation has the potential to become the standard of care for
the treatment of many severe joint diseases, as it significantly
impacts the safety and cost-effectiveness of treatment by providing
longer duration of action, with fewer injections, compared to other
corticosteroid injections and intra-articular steroids. The longer
duration of TH is also noteworthy in the current COVID-19
healthcare environment where patient visits to hospitals should be
reduced and focused on urgent patient needs.”
About MedexusMedexus is a
leading specialty pharmaceutical company with a strong North
American commercial platform. The Company’s vision is to provide
the best healthcare products to healthcare professionals and
patients, through our core values of Quality, Innovation, Customer
Service and Teamwork. Medexus Pharmaceuticals is focused on
the therapeutic areas of auto-immune disease, hematology and
allergy. The Company’s leading products are: Rasuvo™ and Metoject®,
a unique formulation of methotrexate (auto-pen and pre-filled
syringe) designed to treat rheumatoid arthritis and other
auto-immune diseases; IXINITY®, an intravenous recombinant factor
IX therapeutic for use in patients 12 years of age or older with
Hemophilia B – a hereditary bleeding disorder characterized by a
deficiency of clotting factor IX in the blood, which is necessary
to control bleeding; and Rupall®, an innovative allergy medication
with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020Email:
mdp@crescendo-ir.com
Investor Relations
(Canada):Frank CandidoDirect Financial Strategies and
Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexusinc.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
READER ADVISORIES
Forward Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws (“forward-looking
statements”). The words “anticipates”, “believes”,
“expects”, “will”, “plans” and similar expressions are often
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Specific forward-looking statements contained in this news release
include, but are not limited to, statements with respect to future
business operations, the timing of regulatory applications and
approvals and the efficacy and success of certain drug therapies.
These statements are based on factors or assumptions that were
applied in drawing a conclusion or making a forecast or projection,
including assumptions based on historical trends, current
conditions and expected future developments. Since forward-looking
statements relate to future events and conditions, by their very
nature they require making assumptions and involve inherent risks
and uncertainties. The Company cautions that although it is
believed that the assumptions are reasonable in the circumstances,
these risks and uncertainties give rise to the possibility that
actual results may differ materially from the expectations set out
in the forward-looking statements. Material risk factors include
those set out in the Company's most recent MD&A; future capital
requirements and dilution; intellectual property protection and
infringement risks; competition (including potential for generic
competition); reliance on key management personnel; the Company’s
ability to implement its business plan; the Company’s ability to
leverage its United States and Canadian infrastructure to promote
additional growth, including with respect to the infrastructure of
Medexus Inc. and Medac Pharma, Inc. and the potential benefits the
Company expects to derive therefrom;, regulatory approval by the
Canadian health authorities; product reimbursement by third party
payers; patent litigation or patent expiry; litigation risk; stock
price volatility; government regulation; and potential third party
claims. Given these risks, undue reliance should not be placed on
these forward-looking statements, which apply only as of the date
hereof. Other than as specifically required by law, the Company
undertakes no obligation to update any forward-looking statements
to reflect new information, subsequent or otherwise.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024